Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL
Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
Patients with refractory and relapse lymphoblastic leukemia had poor outcome even with marrow
ablative conditioning mostly standard iv-Bu-Cy or Cy-TBI. In this study, we focus on a new
treatment strategy with high-dose chemotherapy regimen consisting of
fludaraibine+cytarabine+cyclophosphamide+etoposide followed by reduced intensity condiotning
regimen consisting of fludarabine, busulfan and post-infusion cyclophophamide.